Journal
JOURNAL OF INVESTIGATIVE DERMATOLOGY
Volume 132, Issue 8, Pages 2050-2059Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/jid.2012.117
Keywords
-
Categories
Ask authors/readers for more resources
Mycosis fungoides (MF) is the most common type of primary cutaneous T-cell lymphoma (CTCL). To identify a molecular signature characteristic of MF tumor stage, we used a bioinformatic approach involving meta-analysis of publicly available gene expression data sets combined with previously generated gene expression data. Results for a selection of genes were further refined and validated by quantitative PCR and inclusion of additional controls. With this approach, we identified a profile specific for MF tumor stage, consisting of 989 aberrantly expressed genes, the majority of which (718 genes) are statistically significantly more expressed in MF compared with normal skin, inflamed skin, and normal T cells. As expected, the signature contains genes reflecting the highly proliferative characteristic of this T-cell malignancy, including altered expression of cell cycle and kinetochore regulators. We uncovered details of the immunophenotype, suggesting that MF originates from IL-32-producing cells and identified previously unreported therapeutic targets and/or diagnostic markers, for example, GTSF1 and TRIP13. Loss of expression of the NF-kappa B inhibitor, NFKBIZ, may partly explain the enhanced activity of NF-kappa B, which is a hallmark of MF and other CTCLs. Journal of Investigative Dermatology (2012) 132, 2050-2059; doi:10.1038/jid.2012.117; published online 19 April 2012
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available